Article Text

Download PDFPDF
Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?
  1. E. Despierre*,
  2. P. Moerman,
  3. I. Vergote* and
  4. F. Amant*
  1. * Division of Gynecological Oncology, Department of Obstetrics & Gynecology
  2. Department of Anatomic Pathology, University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium
  1. Address correspondence and reprint requests to: Frederic Amant, MD, PhD, Division of Gynecological Oncology, Department of Obstetrics & Gynecology, University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium. Email: frederic.amant{at}


Serous endometrial carcinoma (SEC) is an uncommon variant of endometrial carcinoma that is notorious for its aggressive clinical course. Similar to its ovarian counterpart, it has a propensity for early intraabdominal and lymphatic spread. We present two cases of advanced SEC, who were left with no residual tumor after neoadjuvant chemotherapy. After three courses of chemotherapy, both patients underwent interval debulking surgery, resulting in no residual disease. The documentation of chemosensitivity might enable the clinician to select a subpopulation of patients with widespread SEC that might benefit from interval debulking surgery.

  • serous
  • NACT
  • intervaldebulking
  • endometrial

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.